Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease
In some patients, psoriasis appears refractory to many treatments, particularly when the disease is confined to some specific body regions. In this respect, palmoplantar psoriasis and palmoplantar pustulosis are possibly related conditions in their immunopathomechanisms involving Il-12, IL-23, and T...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Journal of Biomedicine and Biotechnology |
Online Access: | http://dx.doi.org/10.1155/2012/413767 |
id |
doaj-c0cc4a2fdb0d4bf68d0aa529befa9cff |
---|---|
record_format |
Article |
spelling |
doaj-c0cc4a2fdb0d4bf68d0aa529befa9cff2020-11-25T00:40:29ZengHindawi LimitedJournal of Biomedicine and Biotechnology1110-72431110-72512012-01-01201210.1155/2012/413767413767Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of DiseaseTrinh Hermanns-Lê0Enzo Berardesca1Gérald E. Piérard2Marianne Lesuisse3Claudine Piérard-Franchimont4Department of Dermatopathology, University Hospital of Liège, 4000 Liège, BelgiumSan Gallicano Dermatological Institute, 00144 Roma, ItalyDepartment of Dermatopathology, University Hospital of Liège, 4000 Liège, BelgiumDepartment of Dermatology, Regional Hospital Citadelle, 4000 Liège, BelgiumDepartment of Dermatopathology, University Hospital of Liège, 4000 Liège, BelgiumIn some patients, psoriasis appears refractory to many treatments, particularly when the disease is confined to some specific body regions. In this respect, palmoplantar psoriasis and palmoplantar pustulosis are possibly related conditions in their immunopathomechanisms involving Il-12, IL-23, and Th17. Nail psoriasis and scalp psoriasis are two other particular psoriasis manifestations. Accordingly, ustekinumab was tested in a few of these patients. The present paper is limited to peer-reviewed case reports. Data were not supported by bioinstrumental assessments and controlled trials. Overall, they are indicative of potential efficacy. The cost-effectiveness and the risk-benefit assessments merit further investigations.http://dx.doi.org/10.1155/2012/413767 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Trinh Hermanns-Lê Enzo Berardesca Gérald E. Piérard Marianne Lesuisse Claudine Piérard-Franchimont |
spellingShingle |
Trinh Hermanns-Lê Enzo Berardesca Gérald E. Piérard Marianne Lesuisse Claudine Piérard-Franchimont Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease Journal of Biomedicine and Biotechnology |
author_facet |
Trinh Hermanns-Lê Enzo Berardesca Gérald E. Piérard Marianne Lesuisse Claudine Piérard-Franchimont |
author_sort |
Trinh Hermanns-Lê |
title |
Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease |
title_short |
Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease |
title_full |
Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease |
title_fullStr |
Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease |
title_full_unstemmed |
Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease |
title_sort |
challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of disease |
publisher |
Hindawi Limited |
series |
Journal of Biomedicine and Biotechnology |
issn |
1110-7243 1110-7251 |
publishDate |
2012-01-01 |
description |
In some patients, psoriasis appears refractory to many treatments, particularly when the disease is confined to some specific body regions. In this respect, palmoplantar psoriasis and palmoplantar pustulosis are possibly related conditions in their immunopathomechanisms involving Il-12, IL-23, and Th17. Nail psoriasis and scalp psoriasis are two other particular psoriasis manifestations. Accordingly, ustekinumab was tested in a few of these patients. The present paper is limited to peer-reviewed case reports. Data were not supported by bioinstrumental assessments and controlled trials. Overall, they are indicative of potential efficacy. The cost-effectiveness and the risk-benefit assessments merit further investigations. |
url |
http://dx.doi.org/10.1155/2012/413767 |
work_keys_str_mv |
AT trinhhermannsle challengingregionalpsoriasisandustekinumabbiotherapyimpactofthepatternsofdisease AT enzoberardesca challengingregionalpsoriasisandustekinumabbiotherapyimpactofthepatternsofdisease AT geraldepierard challengingregionalpsoriasisandustekinumabbiotherapyimpactofthepatternsofdisease AT mariannelesuisse challengingregionalpsoriasisandustekinumabbiotherapyimpactofthepatternsofdisease AT claudinepierardfranchimont challengingregionalpsoriasisandustekinumabbiotherapyimpactofthepatternsofdisease |
_version_ |
1725289725943611392 |